Published January 11, 2023 | Version v1
Journal article Open

Selected strategies to fight pathogenic bacteria

Authors/Creators

  • 1. Latvian Institute of Organic Synthesis, Riga, Latvia; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Riga Stradiņš University, Riga, Latvia
  • 2. Latvian Institute of Organic Synthesis, Riga, Latvia
  • 3. Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, Italy
  • 4. Center for Peptide-Based Antibiotics, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen East, Denmark
  • 5. Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
  • 6. Infla-Med, Centre of Excellence, University of Antwerp, Antwerp, Belgium; Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium
  • 7. Laboratory for Microbiology, Parasitology and Hygiene (LMPH), Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium
  • 8. Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Finland
  • 9. Latvian Institute of Organic Synthesis, Riga, Latvia; Institute of Technology of Organic Chemistry, Faculty of Materials Science and Applied Chemistry, Riga Technical University, Riga, Latvia

Description

 Natural products and analogues are a source of antibacterial drug discovery. Considering drug resistance levels emerging for antibiotics, identification of bacterial metalloenzymes and the synthesis of selective inhibitors are interesting for antibacterial agent development. Peptide nucleic acids are attractive antisense and antigene agents representing a novel strategy to target pathogens due to their unique mechanism of action. Antisense inhibition and development of antisense peptide nucleic acids is a new approach to antibacterial agents. Due to the increased resistance of biofilms to antibiotics, alternative therapeutic options are necessary. To develop antimicrobial strategies, optimised in vitro and in vivo models are needed. In vivo models to study biofilm-related respiratory infections, device-related infections: ventilator-associated pneumonia, tissue-related infections: chronic infection models based on alginate or agar beads, methods to battle biofilm-related infections are discussed. Drug delivery in case of antibacterials often is a serious issue therefore this review includes overview of drug delivery

Files

Selected strategies to fight pathogenic bacteria.pdf

Files (4.5 MB)

Additional details

Funding

European Commission
SPRINGBOARD - Springboard for excellence in advanced development of antibacterials 951883